Aparna A. Kamat, MD

Associate Professor of Clinical Obstetrics and Gynecology, Academic Institute
Department of Obstetrics & Gynecology
Cancer Center
Houston Methodist Hospital
Houston Methodist
Weill Cornell Medical College

Source: Scopus
Calculated based on no. of publications stored in Pure and citations from Scopus

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Dr. Aparna Kamat is the director of the Division of Gynecologic Oncology for Houston Methodist and is currently the section leader for the Gynecologic Oncology service line. After completing medical training in India, Dr. Kamat completed her residency in OB/GYN at West Virginia University where she served as chief resident.

She completed her fellowship training in Gynecologic Oncology at the MD Anderson Cancer Center. During her fellowship, she received multiple awards for her research in ovarian cancer and endometrial cancer including the Virginia K. Pierce award and the Asche Murray fellowship. She also received the prestigious BIRCWH award from the N.I.H. for her research in biomarkers for ovarian cancer. Dr. Kamat currently is the principle investigator for the Gynecologic Oncology Group Clinical Trials Program at Houston Methodist and offers several state-of-the-art clinical trials for patients with gynecologic malignancies.

Her areas of expertise are robotic and minimally invasive surgical options for women with gynecologic cancers and complex pelvic disease. Her other clinical interests include hereditary risk assessment and treatment of gynecologic malignancies.

Research Area Keywords

Cancer

Free-text keywords

Gynecologic cancer
Pelvic disease
Hereditary risk assessment
Minimally invasive surgery
Gynecologic malignancy

Fingerprint

Dive into the research topics where Aparna A. Kamat is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

2 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.

22 Active

Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy (VOCAL)
Kamat, A. A., Alaniz, A., Suri, A. & Zaid, T.
3/12/20 → …
Project: Clinical Trial
A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum (GOG-3026)
Kamat, A. A., Alaniz, A., Darcourt, J., Singh, M., Suri, A. & Zaid, T.
12/19/19 → …
Project: Clinical Trial
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NRG-GY009)
Kamat, A. A., Alaniz, A., Darcourt, J., Singh, M., Suri, A. & Zaid, T.
7/17/19 → …
Project: Clinical Trial
A Phase III Randomized
Kamat, A. A., Darcourt, J., Singh, M., Suri, A. & Zaid, T.
3/1/19 → 2/28/25
Project: Non Profit
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer (NRG-GY006)
Zaid, T., Butler, E. B., Darcourt, J., Farach, A. M., Kamat, A. A., Morgan, P. B., Shkedy, C., Singh, M. & Suri, A.
2/22/19 → …
Project: Clinical Trial

5742 Citations
38 h-Index
47 Article
3 Review article
2 Comment/debate
1 Chapter
1 More
- 1 Conference contribution

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
TRINOVA-3/ENGOT-ov2/GOG-3001 investigators, Jun 2019, In : The Lancet Oncology. 20, 6, p. 862-876 15 p.
Research output: Contribution to journal › Article
11 Scopus citations
Non-16/18 high-risk HPV infection predicts disease persistence and progression in women with an initial interpretation of LSIL
Lyons, Y. A., Kamat, A. A., Zhou, H., Mody, D. R., Schwartz, M. R., Hobday, C. & Ge, Y., Jul 2015, In : Cancer cytopathology. 123, 7, p. 435-442 8 p.
Research output: Contribution to journal › Article
8 Scopus citations
Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma
Gillet, J. P., Calcagno, A. M., Varma, S., Davidson, B., Elstrand, M. B., Ganapathi, R., Kamat, A. A., Sood, A. K., Ambudkar, S. V., Seiden, M. V., Rueda, B. R. & Gottesman, M. M., Jun 1 2012, In : Clinical Cancer Research. 18, 11, p. 3197-3206 10 p.
Research output: Contribution to journal › Article
32 Scopus citations
Ovarian cancer
Bhosale, P., Kamat, A. & Eifel, P. J., Jan 1 2012, Oncologic Imaging: A Multidisciplinary Approach. Elsevier Health Sciences, p. 455-478 24 p.
Research output: Chapter in Book/Report/Conference proceeding › Chapter

1 Scopus citations
Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors
Liggett, T. E., Melnikov, A., Yi, Q., Replogle, C., Hu, W., Rotmensch, J., Kamat, A., Sood, A. K. & Levenson, V., Jan 2011, In : Gynecologic oncology. 120, 1, p. 113-120 8 p.
Research output: Contribution to journal › Article
72 Scopus citations